Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K.' s NICE To Evaluate Efficacy of Bristol's Taxol In Ovarian Cancer

Executive Summary

The U.K.' s National Institute of Clinical Excellence plans an assessment of ovarian cancer therapies with Bristol-Myers Squibb's Taxol (paclitaxel) as one of its first priorities, the Department of Health announced Aug. 6.

You may also be interested in...



Glaxo Decides Not To Pursue U.K. Flu Awareness Campaign For Relenza

The potential negative impact on the U.K.' s National Health Service drug budget may be one factor behind Glaxo Wellcome's decision not to launch a flu awareness campaign for its neuraminidase inhibitor Relenza (zanamivir) in the U.K.

Glaxo Decides Not To Pursue U.K. Flu Awareness Campaign For Relenza

The potential negative impact on the U.K.' s National Health Service drug budget may be one factor behind Glaxo Wellcome's decision not to launch a flu awareness campaign for its neuraminidase inhibitor Relenza (zanamivir) in the U.K.

U.K. Regulators To Consider FDA-Style Transparency

The U.K.' s Medicines Control Agency will consider the adoption of FDA-style transparency to communicate information about its activities more effectively, according to a five-year review of the agency conducted by the U.K. Department of Health.

Related Content

UsernamePublicRestriction

Register

PS034697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel